ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0009

Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial

Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), autoantigens, autoimmune diseases, B-Cell Targets, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B cells play a significant role in the pathogenesis by producing autoantibodies, secreting unique cytokines, and activating other immune cells. Rituximab (RTX), a chimeric monoclonal antibody that targets the B-cell specific antigen CD20, has shown efficacy in treating SSc. The DESIRES trial (NCT04274257) demonstrated RTX’s superiority over placebo in reducing the modified Rodnan skin score (mRSS) 24 weeks post-treatment, with a noted association between decreased serum immunoglobulin levels and RTX responsiveness. However, this decrease could not be explained by changes in SSc-related autoantibodies like anti-topoisomerase I antibody (ATA), anti-centromere antibody (ACA), or anti-RNA polymerase III antibody (ARA), prompting further investigation.

Methods: In the DESIRES trial, 56 SSc patients were evenly randomized to receive RTX or placebo. Serum samples collected at the start and 24 weeks post-treatment were used for proteome-wide autoantibody screening (PWAS; Figure 1A). PWAS was conducted using wet protein arrays that display 13,350 human antigens. After excluding unsuitable samples, the study proceeded with 24 patients in the RTX group, 21 in the placebo group, and 45 sex and age-matched healthy controls (HCs; Figure 1B). Patients with mRSS improvement of 7 or higher and 6 or lower 24 weeks post-treatment were classified as high responders (HRs) and low responders (LRs), respectively. Clinically relevant autoantibodies were defined as those serum levels differentially elevated in SSc compared to HCs, higher in HRs than in LRs at baseline, and significantly reduced pre- and post-RTX administration in HRs.

Results: Sum of autoantibody levels (SAL) was significantly higher in SSc patients compared to HCs (Figure 1C). RTX treatment group was categorized into HRs (n = 11) and LRs (n = 13; Figure 1D). HRs showed greater initial SAL and significant reductions post-treatment, unlike LRs (Figure 1E). No such trend was observed in SSc-related autoantibodies, including ATA, ACA, and ARA (Figure 1F). We identified 58 clinically relevant autoantibodies (Figure 2A, B, C, and D), primarily targeting membrane proteins, including G protein-coupled receptors (Figure 2E), which provided near-perfect differentiation between HRs and LRs (Figure 2F). Weighted correlation network analysis identified clustering of most clinically relevant autoantibodies with ATA in the “turquoise” module, correlating with clinical traits of SSc, including mRSS and patient-reported quality of life (Figure 3).

Conclusion: This study applied PWAS to serum samples collected in the DESIRES trial, revealing a significant elevation of autoantibody levels in SSc compared to HCs. We identified 58 clinically relevant autoantibodies responsive to RTX therapy. These findings underscore the potential of comprehensive autoantibody profiling in enhancing diagnostic and therapeutic strategies for SSc, and in deciphering the pathogenesis of SSc.

Supporting image 1

Figure 1

Supporting image 2

Figure 2

Supporting image 3

Figure 3


Disclosures: K. Matsuda: None; S. Sato: None; A. Yoshizaki: Japan Cosmetic Association, 5, Japan Federation of Medium and Small Enterprise Organizations, 5.

To cite this abstract in AMA style:

Matsuda K, Sato S, Yoshizaki A. Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comprehensive-autoantibody-profiling-highlights-clinical-relevance-of-autoantibodies-to-g-protein-coupled-receptors-in-systemic-sclerosis-insights-from-a-b-cell-depletion-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comprehensive-autoantibody-profiling-highlights-clinical-relevance-of-autoantibodies-to-g-protein-coupled-receptors-in-systemic-sclerosis-insights-from-a-b-cell-depletion-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology